Cantor Fitzgerald Estimates Annexon FY2025 Earnings

Annexon, Inc. (NASDAQ:ANNX - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Annexon in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will earn ($0.99) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Annexon's current full-year earnings is ($0.96) per share.

Other equities analysts also recently issued reports about the stock. Needham & Company LLC restated a "buy" rating and issued a $16.00 target price on shares of Annexon in a research note on Friday, November 15th. HC Wainwright restated a "buy" rating and issued a $30.00 price target on shares of Annexon in a report on Tuesday, December 17th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Annexon presently has an average rating of "Buy" and a consensus price target of $15.80.

Annexon Stock Performance

Annexon stock traded down $0.02 during mid-day trading on Wednesday, hitting $4.16. The company's stock had a trading volume of 1,002,753 shares, compared to its average volume of 1,474,850. Annexon has a one year low of $3.86 and a one year high of $8.40. The stock has a market cap of $442.88 million, a PE ratio of -3.96 and a beta of 1.11. The company has a 50 day moving average of $5.13 and a 200-day moving average of $5.93.

Institutional Investors Weigh In On Annexon

A number of institutional investors have recently modified their holdings of ANNX. Parkman Healthcare Partners LLC boosted its holdings in shares of Annexon by 0.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 328,613 shares of the company's stock worth $1,945,000 after purchasing an additional 1,768 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Annexon by 1.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 159,586 shares of the company's stock worth $945,000 after acquiring an additional 2,450 shares during the last quarter. GSA Capital Partners LLP increased its holdings in Annexon by 10.7% in the 3rd quarter. GSA Capital Partners LLP now owns 34,581 shares of the company's stock valued at $205,000 after purchasing an additional 3,355 shares during the last quarter. MetLife Investment Management LLC lifted its stake in Annexon by 11.8% during the third quarter. MetLife Investment Management LLC now owns 55,212 shares of the company's stock worth $327,000 after purchasing an additional 5,814 shares in the last quarter. Finally, Creative Planning grew its position in Annexon by 29.5% in the 3rd quarter. Creative Planning now owns 34,779 shares of the company's stock valued at $206,000 after acquiring an additional 7,914 shares in the last quarter.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.